ONGOING
No. Research Title Investigator Status
1 AEGIS II – A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of CSL112 in Subject with Acute Coronary Syndrome Dato’ Sri Dr. Haji Azhari Rosman Enrollment
2 APPIRED III – Preventing Oxidative Stress Induced Ischemic Injury and Systemic Inflammation Complications During and After Invasive Cardiac Surgery with Alkaline Phosphatase Dr. Pau Kiew Kong Enrollment
3 ABILITY DIABETES – Randomized Comparison of Abluminus DES+ Sirolimus-Eluting Stents versus Everolimus-Eluting Stents in Coronary Artery Disease Patients with Diebetes Mellitus Global. Dato’ Dr. Amin Ariff Nuruddin Enrollment
4 COMBINE-INTERVENE – COMBINEd Ischemia and Vulnerable Plaque Percutaneous INTERVENtion to Reduce Cardiovascular Events. Dato’ Dr. Amin Ariff Nuruddin Enrollment
5 LEADR: Lead Evaluation for Defibrillation and Reliability Dr. Surinder Kaur Khelae Enrollment
6 CTO Registry using the HYBRID CTO ALGORITHM at IJN. (Device : Crossboss & Stingray) Datuk Dr. Shaiful Azmi Yahaya Enrollment
7 FINEARTS – A multicentre, randomized, double-blind, parallel-group, placebo-controlled study to evaluate the efficacy and safety of finerenone on morbidity and mortality in participants with heart failure(NYHA II-IV) and EF ≥40% Dr. Teoh Chee Kiang Enrollment
8 DEDICATE REGISTRY – A Post Market Registry of Abluminum® Sirolimus Eluting Coronary Stent System for Percutaneous Intervention in Patients with Diabetic Mellitus Dato’ Sri Dr. Haji Azhari Rosman Enrollment
9 GSR DEFINE: Global SYMPLICITY Registry (GSR) Denervation Findings in Real World (DEFINE) is referred to as the GSR DEFINE study Dato’ Dr. Amin Ariff Nuruddin Enrollment
10 FIM-IBS – A Prospective, Non-randomized, Open lable, Non-comparative, First-in-Man Study to Evaluate the Feasibility and Safety of Sirolimus-eluting Iron Bioresorbable Coronary Scaffold System Datuk Dr. Shaiful Azmi Yahaya Enrollment
11 ZEUS-Effects of ziltivekimab versus placebo on cardiovascular outcomes in participants with established atherosclerotic cardiovascular disease, chronic kidney disease and systemic inflammation Dato’ Sri Dr. Haji Azhari Rosman Enrollment
12 MID-Q Response Datuk Dr. Azlan Hussin Enrollment
13 NEOS-APAC-Asian Pacific post-market clinical follow-up study in patients with acute or chronic aortic dissection or aortic aneurysm treated with E-vita OPEN NEO Mr. Paneer Selvam Enrollment
14 RESTORE: A Prospective, Multicenter, Single-Arm, Open-Label, Phase 4 Study of the Effects of Selexipag on Right Ventricular Remodeling in Pulmonary Arterial Hypertension Assessed by Cardiac Magnetic Resonance Imaging Dr. Geetha A/P Kandavello @ Kandhavel Enrollment
15 TOMORROW – A Multicenter, Open-label, Randomized, Event-driven Study to Assess Efficacy, Safety and Pharmacokinetics of Macitentan Versus Standard of Care in Children with Pulmonary Arterial Hypertension Dr. Geetha A/P Kandavello @ Kandhavel Enrollment
16 VFAHF STUDY – Ventricle from Atrium Heart Failure Clinical Study (VFAHF) Datuk Dr. Azlan Hussin Enrollment
17 SALTO – A Randomized, Multicenter, Double-Blind, Placebo-Controlled, Parallel-Group, Event-Driven, Group-Sequential Study with Open-Label Extension Period to Assess the Efficacy and Safety of Selexipag as Add-On Treatment to Standard of Care in Children Aged ≥2 to <18 years with Pulmonary Arterial Hypertension Dr. Geetha A/P Kandavello @ Kandhavel Enrollment
18 SCORE REGISTRY: Sequent® SCB ‘’All Comers’’ Post Market Clinical Follow up (PMCF) Dato’ Dr. Amin Ariff Nuruddin Enrollment
19 STRIDE: Effects of semaglutide on functional capacity in patients withtype 2 diabetes and peripheral arterial disease Datuk Dr. Shaiful Azmi Yahaya Enrollment
20 PRIME-FFR: Prognostic impact of lesion-specific hemodynamic index and disease characteristics in patients with coronary artery disease assessed by fractional flow reserve Dato’ Sri Dr. Haji Azhari Rosman Enrollment
       
No. Research Title Investigator Status
1 BIOLUX P-III REGISTRY: BIOTRONIK-A Prospective, International, Multi-Centre, Post-Market All-Comers Registry To Assess The Clinical Performance Of The Passeo-18 Lux Paclitaxel Releasing Balloon Catheter In Infraguinal Arteries -III Datuk Dr. Shaiful Azmi Yahaya Follow Up
2 Meres-1 Extend: A Prospective, Multinational, Multicenter, Single Arm, Open Label, Pilot Clinical Study Of Meres100 Sirolimus Eluting Bioresorbable Vascular Scaffold System In The Treatment Of De-Novo Native Coronary Artery Lesions Dato’ Dr. Amin Ariff Nuruddin Follow Up
3 ABSORB BVS: Comparative Study In Real World Use Of The ABSORB Bioresorbable Vascular Scaffold In De Novo Coronary Artery Disease Among Diabetes And Non-Diabetes Patient In Institut Jantung Negara, Malaysia: A Prospective Post-Marketing Single-Center Registry Datuk Dr. Shaiful Azmi Yahaya Follow Up
4 CONSEQUENT ALL COMERS: Clinical PMCF on Peripheral Arteries treated with SeQuent® Please OTW Paclitaxel Coated Balloon Catheter in an All Comer Patient Population Datuk Dr. Shaiful Azmi Yahaya Follow Up
5 ISCHEMIA – International Study of Comparative Health Effectiveness With Medical and Invasive Approaches Datuk Dr. Ahmad Khairuddin Mohamed Yusof Follow Up
6 The EASTBOURNE Registry: The All-comers Sirolimus-coated balloon European registry. Dato’ Dr. Amin Ariff Nuruddin Follow Up
7 SCB DE-NOVO STUDY: Treatment of coronary de-novo stenosis by a sirolimus coated balloon or a paclitaxel coated balloon catheter Dato’ Dr. Amin Ariff Nuruddin Follow Up
8 BIOSOLVE-IV REGISTRY: Safety And Performance In De Novo Lesion Of Native Coronary Arteries With Magmaris – Registry Data Dato’ Dr. Amin Ariff Nuruddin Follow Up
9 MYHF: Malaysian National Heart Failure Registry Dato’ Dr. Azmee Bin Mohd Ghazi Follow Up
10 SELECT STUDY: Semaglutide effects on cardiovascular outcomes in people with overweight or obesity Dato’ Sri Dr. Haji Azhari Rosman Follow Up
11 BGSAMIRP: Blood-based Genomic Signatures in Acute Myocardial Infarction Risk Prediction Dato’ Dr. Amin Ariff Nuruddin Follow Up
12 CAAN-AF: Cardiac Resynchronization therapy (CRT) And AV Node ablation in Atrial Fibrillation Datuk Dr. Azlan Hussin Follow Up
13 PROTECT-ICD Trial: Programmed Ventricular Stimulation to Risk Stratify for Early Cardioverter-Defibrillator (ICD) Implantation to Prevent Tachyarrhythmias Following Acute Myocardial Infarction Dr. Geetha A/P Kandavello @ Kandhavel Follow Up
14 CRYO AF GLOBAL REGISTRY Dr. Surinder Kaur Khelae Follow Up
15 A DUE: Prospective, multi-center, double-blind, randomized, active-controlled, triple-dummy, parallel-group, group-sequential, adaptive Phase 3 clinical study to compare the efficacy and safety of macitentan and tadalafil monotherapies with the corresponding fixed dose combination in subjects with pulmonary arterial hypertension (PAH), followed by an open-label treatment period with macitentan and tadalafil fixed dose combination therapy Dr. Geetha A/P Kandavello @ Kandhavel Follow Up
16 BIOFLOW-DAPT: BIOTRONIK – A Prospective, Randomized, Multi-center Study to Assess the SaFety of the Orsiro Mission Stent compared to the ResoLute Onyx Stent in Subjects at High Risk for Bleeding in combination With 1-month Dual Antiplatelet Therapy (DAPT) Datuk Dr. Shaiful Azmi Yahaya Follow Up
17 MICRA AV: Product Surveillance Registry (PSR) Datuk Dr. Azlan Hussin Follow Up
As at 29 Nov 2022
COMPLETED
Book an Appointment
judi online